Insider share sale at current price of US$61.62 raises caution. More insider shares sold than bought over the past year is concerning. High insider ownership could indicate alignment of management and shareholder interests.
More insider selling than buying at Terex in the last three months and over the past year could be seen as a bearish signal. Despite Terex's profitability and growth, the low level of insider ownership might suggest a lack of alignment between insiders and shareholders.
Market sentiment seems negative towards the company, indicated by its low P/E ratio of 7.78. Despite recent insider buying, earnings and revenue growth trends are deemed crucial for future stock performance.
Despite modest growth projections, Terex's current undervaluation suggests it may be a good time to increase holdings in this stock. The future outlook is not fully reflected in the current share price, indicating it's not too late to invest.
The upwards trend in Terex's ROCE indicates improvements in the company's efficiencies which is taken as a positive sign. It's worth researching the company further to see if these trends are likely to persist.
特雷克斯股票討論區
近5年毛利率基本在19%左右,只有2020年跌到了17.5%。淨資產收益率則從9.5%上升到21.75%,只有2020年為-1.1%,5年平均為9.4%,看起來沒什麼吸引力。
營收2020年觸底,2021年仍沒恢復到2019年的水平。營業利潤也類似,2021年接近了2019年水平。由於2019年有1.55億的停止經營虧損,所以顯得2021年淨利潤大幅超過2019年,如果刨除這部分影響,2019年淨利潤增長並不多。
2022前兩季度營收、營業利潤和淨利潤分別增長9.3%,-3%,10.5%,淨利潤增長主要來自利息費用和其他費用下降。
目前11.83倍市盈率,11.15倍市盈率TTM吸引力不大。
專欄Today's pre-market stock movers: TWTR, UPS, HSBC, JBLU and more
• $Avadel Pharmaceuticals(AVDL.US)$ +36.1% (continued volatility)
• $Gamida Cell(GMDA.US)$ +20.57% (announces FDA clearance of investigational IND and removal of clinical hold for GDA-201)
• $Venator Materials(VNTR.US)$ +14.61% (VNTR receives $85 mln settlement from Tronox)
• $歐伊諾(OI.US)$ +10.9% (earnings report)
• $康寧(GLW.US)$ +9% (earnings report)
• $Arch Resources(ARCH.US)$ +7.2% (earnings report)
• $宣偉公司(SHW.US)$ +6.1% (ea...
專欄Top upgrades and downgrades on 4/8
• $Afya Ltd(AFYA.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $18)
• $Appfolio(APPF.US)$: KeyBanc Upgrades to Overweight from Sector Weight - PT $143
• $羅賓遜物流(CHRW.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $117 (from $91)
• $Coupang(CPNG.US)$: Goldman Sachs Upgrades to Conviction Buy from Buy - PT $37
• $Gatos Silver(GATO.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $4
• $ITT Inc(ITT.US)$: UBS Upgr...
暫無評論